- Home
- IMA vs LSTA Comparison
IMA vs LSTA Comparison
Compare IMA & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMA | LSTA |
|---|---|---|
| Founded | 2019 | 1980 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 45.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | IMA | LSTA |
|---|---|---|
| Price | $5.67 | $3.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.00 | $15.00 |
| AVG Volume (30 Days) | ★ 371.8K | 73.5K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $3.94 | $1.81 |
| 52 Week High | $17.50 | $5.07 |
Technical Indicators
Market Signals| Indicator | IMA | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 12.03 |
| Support Level | $3.94 | $2.29 |
| Resistance Level | $7.28 | $4.84 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | 0.14 | -0.18 |
| Stochastic Oscillator | 63.52 | 7.14 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.